Andrew Peterson, MD, discusses the quality-of-life impact of post-cancer incontinence and advances in electronically controlled artificial urinary sphincters.

The safety and efficacy of vibegron are supported by data from the phase 3 COURAGE and EMPOWUR trials.

Eugene Cone, MD, discusses SWOG S1602 findings comparing Tokyo-172 and TICE BCG and the potential role of alternative BCG strains in NMIBC

EG110A is an investigational DNA medicine under development for neurogenic detrusor overactivity with urinary incontinence.

Juan Gómez-Rivas, MD, discusses barriers to PSMA-PET imaging and how disparities in access may affect prostate cancer staging and treatment planning.

Jonathan Harper, MD, discusses findings from the PUSH trial may inform counseling on hydration and stone recurrence.

Cameron C. Jones, MD, discusses patient selection for Aquablation, including prostate size, anatomy, and factors that may favor alternative BPH procedures.

John P. Sfakianos, MD, discusses the challenges of managing recurrent LG-IR-NMIBC and the role of chemoablation.